"If anything, 2015 list prices will grow more quickly than in 2014," said Richard Evans, a former drug-industry pricing official now an analyst at SSR Health LLC.
The $1,000-a-day price of a new hepatitis C pill has put more attention on the rising cost of drugs.
Yet the hefty price tags of new medicines like Sovaldi from Gilead Sciences Inc., weren't the only culprit in higher drug costs, according to drug-industry analysts. Price increases on older drugs played a big part, too--and the costs are expected to keep soaring.
Brand-name drug prices surged 14% in the 12 months through the end of the third quarter in 2014, adding $32 billion to drug spending, said Elliot Wilbur, a Needham & Co. analyst. Generic drugs, which are supposed to be an instrument for cutting drug spending, have also increased.
Read more: http://www.nasdaq.com/article/drug-prices-to-get-more-expensive--corporate-outlook-20150104-00034#ixzz3NyJmCyAw
Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here
Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.
Alan Franciscus
Editor-in-Chief
HCV Advocate
Showing posts with label rising prices. Show all posts
Showing posts with label rising prices. Show all posts
Monday, January 5, 2015
Subscribe to:
Posts (Atom)